JP2023551122A - 化合物およびタキキニン受容体介在性障害の治療におけるその使用 - Google Patents

化合物およびタキキニン受容体介在性障害の治療におけるその使用 Download PDF

Info

Publication number
JP2023551122A
JP2023551122A JP2023528102A JP2023528102A JP2023551122A JP 2023551122 A JP2023551122 A JP 2023551122A JP 2023528102 A JP2023528102 A JP 2023528102A JP 2023528102 A JP2023528102 A JP 2023528102A JP 2023551122 A JP2023551122 A JP 2023551122A
Authority
JP
Japan
Prior art keywords
nk2r
group
amino acids
agonist
agonist according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551122A5 (https=
Inventor
バーント フレデリク グスタフソン，マグナス
マッドセン，ジョニー
ムルバッド，オリビア
フレデリク ジョアン ホーゲンドーフ，ウォウター
ボンド ハンセン，ジェイコブ
Original Assignee
エンバーク バイオテック エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンバーク バイオテック エーピーエス filed Critical エンバーク バイオテック エーピーエス
Publication of JP2023551122A publication Critical patent/JP2023551122A/ja
Publication of JP2023551122A5 publication Critical patent/JP2023551122A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023528102A 2020-11-09 2021-11-09 化合物およびタキキニン受容体介在性障害の治療におけるその使用 Pending JP2023551122A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20206509 2020-11-09
EP20206509.0 2020-11-09
PCT/EP2021/081057 WO2022096736A1 (en) 2020-11-09 2021-11-09 Compounds and their use in treatment of tachykinin receptor mediated disorders

Publications (2)

Publication Number Publication Date
JP2023551122A true JP2023551122A (ja) 2023-12-07
JP2023551122A5 JP2023551122A5 (https=) 2024-10-30

Family

ID=73198203

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528102A Pending JP2023551122A (ja) 2020-11-09 2021-11-09 化合物およびタキキニン受容体介在性障害の治療におけるその使用

Country Status (13)

Country Link
US (1) US20230406883A1 (https=)
EP (1) EP4240749A1 (https=)
JP (1) JP2023551122A (https=)
KR (1) KR20230106616A (https=)
CN (1) CN116745310A (https=)
AU (1) AU2021374843A1 (https=)
CA (1) CA3197916A1 (https=)
CL (1) CL2023001325A1 (https=)
CO (1) CO2023007404A2 (https=)
IL (1) IL302745A (https=)
MX (1) MX2023005408A (https=)
PE (1) PE20231952A1 (https=)
WO (1) WO2022096736A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
WO2023118263A1 (en) * 2021-12-21 2023-06-29 Embark Biotech Aps Agonists for treatment of eating disorder
CN117384258B (zh) * 2023-10-12 2024-07-26 湖南中晟全肽生物科技股份有限公司 一种神经激肽受体2（nk2r）激动剂及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505284A (ja) * 2013-11-15 2017-02-16 ノヴォ ノルディスク アー／エス 選択的なｐｙｙ化合物及びその使用
JP2018522843A (ja) * 2015-06-12 2018-08-16 ノヴォ ノルディスク アー／エス 選択的ｐｙｙ化合物及びその使用
WO2019059963A1 (en) * 2017-09-21 2019-03-28 Dignify Therapeutics, Llc COMPOSITIONS FOR INDUCING MICTION AND DEFECATION

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2427475T3 (pl) * 2009-05-08 2021-07-19 Techfields Biochem Co., Ltd. Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami
US11633459B2 (en) * 2018-05-04 2023-04-25 Novo Nordisk A/S GIP derivatives and uses thereof
MX2022004566A (es) * 2019-10-17 2022-07-21 Univ Copenhagen Agonista del receptor de taquiquinina 2 (tacr2).

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505284A (ja) * 2013-11-15 2017-02-16 ノヴォ ノルディスク アー／エス 選択的なｐｙｙ化合物及びその使用
JP2018522843A (ja) * 2015-06-12 2018-08-16 ノヴォ ノルディスク アー／エス 選択的ｐｙｙ化合物及びその使用
WO2019059963A1 (en) * 2017-09-21 2019-03-28 Dignify Therapeutics, Llc COMPOSITIONS FOR INDUCING MICTION AND DEFECATION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAU J. ET AL.: "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analpgues Semaglutide", J MED CHEM, vol. 58, JPN6025044138, 2015, pages 7370 - 7380, ISSN: 0005723006 *

Also Published As

Publication number Publication date
CO2023007404A2 (es) 2023-07-10
EP4240749A1 (en) 2023-09-13
WO2022096736A1 (en) 2022-05-12
MX2023005408A (es) 2023-07-25
KR20230106616A (ko) 2023-07-13
IL302745A (en) 2023-07-01
US20230406883A1 (en) 2023-12-21
AU2021374843A9 (en) 2024-08-08
CN116745310A (zh) 2023-09-12
CA3197916A1 (en) 2022-05-12
AU2021374843A1 (en) 2023-06-08
PE20231952A1 (es) 2023-12-06
CL2023001325A1 (es) 2023-12-15

Similar Documents

Publication Publication Date Title
KR102440323B1 (ko) 인크레틴 유사체 및 그의 용도
KR102444783B1 (ko) 인크레틴 유사체 및 그의 용도
JP2023551122A (ja) 化合物およびタキキニン受容体介在性障害の治療におけるその使用
US7186694B2 (en) Leptin-related peptides
JP3765831B2 (ja) 改善された環状ｃｒｆ作用薬
US12410227B2 (en) Incretin analogs and uses thereof
JP2022509568A (ja) 修飾されたｇｉｐペプチド類似体
CN1976948A (zh) 修饰的Exendins及其应用
KR20110043686A (ko) 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 유사체
US7208572B2 (en) Leptin-related peptides
US11572399B2 (en) Long-acting GIP peptide analogues
CN100425282C (zh) 用于治疗性干预的y2/y4选择性受体激动剂
WO2023207107A1 (zh) Glp-1/gcg受体共激动剂、包含其的药物组合物及其用途
KR20190017017A (ko) 프로테아제-내성 모노-지질화된 펩타이드
AU2005224027A1 (en) Y2/Y4 selective receptor agonists for therapeutic interventions
CN102076353A (zh) 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
KR20250140094A (ko) Gip/glp1/gcg 삼중-수용체 효능제 및 그의 용도
US20070161545A1 (en) Triple polypeptide complexes
WO2023207106A1 (zh) Glp-1/gip受体共激动剂、包含其的药物组合物及其用途
EA049082B1 (ru) Соединения и их применение для лечения нарушений, опосредованных тахикининовым рецептором
US20260125440A1 (en) Incretin analogs and uses thereof
EA043728B1 (ru) Аналоги инкретина и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230921

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231129

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231130

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260203

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260210